SlideShare une entreprise Scribd logo
1  sur  46
Surface Modification of
   Nanoparticles for
Biomedical Applications




                          1
                              1
• Consequently a multi-component
  nanomedical system can be constructed in
  reverse order of controlling events, namely
  from the inside out. The outer components
  are the first to be used. The inner
  components are the last.
lipids, polimers (biocompatible-biodegradable
materials)
Also water is available (liposomes)
The drug can be inserted into the core
Ligands for targeting
Cell Targeting

A. antibodies
B. Peptides
C. Aptamers
D. Other ligands
Antibodies
• Antibodies directed against tissue-specific
  antigens.
Examples
Receptors: Vascular endothelial growth factor
  (VEGF); folate (highly expressed in tumours);
  Transferrin, opiod peptides (Brain),
  Apolipoproteins (ApoE, Brain) , Human
  epidermal growth factor (EGF)

αvβ3 Integrin
Matrix metalloproteinases
APTAMERS
Aptamers are oligonucleic acid molecules that bind a
specific target molecule. Aptamers are usually created
by selecting them from a large random sequence pool,
    but natural aptamers also exist in riboswitches.
  Aptamers can be used for both basic research and
      clinical purposes as macromolecular drugs.
• aptamers offer advantages over antibodies as
  they can be engineered completely in a test
  tube, are readily produced by chemical
  synthesis, possess desirable storage
  properties, and elicit little or no
  immunogenicity in therapeutic applications.
Aptamer target protein or molecule                          Application
PSMA                                                        Prostate cancer diagnosis and therapy
WT1                                            Understanding Wilm's tumor pathogenesis
4,4′-methylenedianiline                  Detecting DNA-damaging compounds
VEGF                                                 Inhibiting angiogenesis
RET                                      Inhibition of pro-growth signaling
HER-3                                                Reducing drug resistance in HER-2+ cancers
TCF-1                                          Colon cancer growth inhibition
Tenascin-C                               Glioblastoma (brain cancer) detection
MUC1                               Breast, pancreatic, ovarian cancers; targeting demonstrated
PDGF/PDGFR                         Improving transport to tumors and targeting brain cancers
NF-κB                              Targeting a transcription factor implicated in many diseases
Phosphatidylcholine:cholesterol liposomes                   Triggering liposome degradation
Raf-1                                          Inhibiting pro-growth signaling
αvβ3 integrin                            Targeting tumor-associated vasculature
Human keratinocyte growth factor                     Inhibiting pro-growth signali
Properties of aptamers versus
                     antibodies
Aptamers                                      Antibodies
Binding affinity nanomolar to picomolar       Binding affinity nanomolar to picomolar
Selection is a chemical process carried out   Selection requires a biological system,
in vitro and can therefore target any          thus it is difficult to raise antibodies
protein                                        to toxins (not tolerated by animal) or non-
Can select for ligands under a variety of     immunogenic targets.
conditions for in vitro diagnostics           Limited to physiologic conditions for
                                              diagnostics
Uniform activity regardless of batch
                                              Screening monoclonal antibodies time
synthesis
                                              consuming and expensive
PK parameters can be changed on demand        Activity of antibodies vary from batch to
Investigator determines target site of        batch
protein                                       Difficult to modify PK parameters
Wide variety of chemical modifications to     Immune system determines target site of
molecule for diverse functions of molecule    protein
Return to original conformation after         Temperature sensitive and undergo
temperature insult                            irreversible denaturation
                                              Limited shelf-life
Unlimited shelf-life
                                              Significant immunogenicity
No evidence of immunogenicity
PEPTIDES
• Peptide sequences recognized by receptors
  responsible of binding can be identified and
  synthesized.

• Examples are peptide sequences derived from
  ApoE apolipoprotein that are recognized by
  LDL receptor on cell membranes
Peptides aptamers
• Peptide aptamers consist of a variable peptide loop attached at
  both ends to a protein scaffold. This double structural constraint
  greatly increases the binding affinity of the peptide aptamer to
  levels comparable to an antibody's (nanomolar range).The variable
  loop length is typically comprised of 10 to 20 amino acids, and the
  scaffold may be any protein which has good solubility and
  compacity properties. Currently, the bacterial protein Thioredoxin-A
  is the most used scaffold protein, the variable loop being inserted
  within the reducing active site, which is a -Cys-Gly-Pro-Cys- loop in
  the wild protein, the two Cysteines lateral chains being able to form
  a disulfide bridge.Peptide aptamer selection can be made using
  different systems, but the most used is currently the yeast two-
  hybrid system.
OTHER LIGANDS
• Natural ligands for receptors can be
  employed.
Examples:
Folate
ApoE
Trasferrin
Via succinimide




+
nanoparticle     nanoparticle




                                   biotin




                        streptavidin

biotin
antibody

                           nanoparticle




           antibody
                      streptavidin



                           biotin
LNA
• A locked nucleic acid (LNA), often
  referred to as inaccessible RNA, is a
  modified RNA nucleotide. The
  ribose moiety is modified with an
  extra bridge connecting the 2'
  oxygen and 4' carbon. LNA
  nucleotides can be mixed with DNA
  or     RNA     residues     in    the
  oligonucleotide whenever desired.
  Such oligomers are commercially
  available. The locked ribose
  conformation      enhances      base
  stacking and backbone pre-
  organization. This significantly
  increases      the      hybridization
  properties (melting temperature)
  of oligonucleotides.[1]
cystein

Contenu connexe

Tendances

Monoclonal antibody
Monoclonal antibodyMonoclonal antibody
Monoclonal antibodyJeenaJoy10
 
nanoparticles in cancer treatment /therpy
nanoparticles in cancer treatment /therpy nanoparticles in cancer treatment /therpy
nanoparticles in cancer treatment /therpy Manisha371125
 
Monoclonal antibodies
Monoclonal antibodiesMonoclonal antibodies
Monoclonal antibodiesdustndreams
 
Monoclonal antibodies Clinical Significance
Monoclonal antibodies Clinical SignificanceMonoclonal antibodies Clinical Significance
Monoclonal antibodies Clinical Significancedrvicky666
 
Monoclonal Antibodies As Therapeutic Agents In Oncology And
Monoclonal Antibodies As Therapeutic Agents In Oncology AndMonoclonal Antibodies As Therapeutic Agents In Oncology And
Monoclonal Antibodies As Therapeutic Agents In Oncology Anddrmisbah83
 
Seminario Biología Molecular
Seminario Biología MolecularSeminario Biología Molecular
Seminario Biología MolecularMariaT47
 
Monoclonal antibody and its delivery
Monoclonal antibody and its deliveryMonoclonal antibody and its delivery
Monoclonal antibody and its deliveryshikha singh
 
viral nanoparticles
viral nanoparticlesviral nanoparticles
viral nanoparticlessaurav saha
 
Monoclonal antibodies in cancer therapy
Monoclonal antibodies in cancer therapy Monoclonal antibodies in cancer therapy
Monoclonal antibodies in cancer therapy SameerKhasbage
 

Tendances (20)

Aptamers
AptamersAptamers
Aptamers
 
Therapeutic antibodies 5_humanization
Therapeutic antibodies 5_humanizationTherapeutic antibodies 5_humanization
Therapeutic antibodies 5_humanization
 
Monoclonal antibody
Monoclonal antibodyMonoclonal antibody
Monoclonal antibody
 
Cell Transfection
Cell TransfectionCell Transfection
Cell Transfection
 
nanoparticles in cancer treatment /therpy
nanoparticles in cancer treatment /therpy nanoparticles in cancer treatment /therpy
nanoparticles in cancer treatment /therpy
 
Monoclonal antibodies
Monoclonal antibodiesMonoclonal antibodies
Monoclonal antibodies
 
Gpcr genetic variation
Gpcr genetic variationGpcr genetic variation
Gpcr genetic variation
 
Monoclonal antibodies Clinical Significance
Monoclonal antibodies Clinical SignificanceMonoclonal antibodies Clinical Significance
Monoclonal antibodies Clinical Significance
 
Monoclonal antibodies
Monoclonal antibodiesMonoclonal antibodies
Monoclonal antibodies
 
Monoclonal Antibodies As Therapeutic Agents In Oncology And
Monoclonal Antibodies As Therapeutic Agents In Oncology AndMonoclonal Antibodies As Therapeutic Agents In Oncology And
Monoclonal Antibodies As Therapeutic Agents In Oncology And
 
Chemical method of transformation
Chemical method of transformation Chemical method of transformation
Chemical method of transformation
 
Monoclonal Antibodies and their role in Pharmacology
Monoclonal Antibodies and their role in Pharmacology  Monoclonal Antibodies and their role in Pharmacology
Monoclonal Antibodies and their role in Pharmacology
 
G4 antimicrobial drug resistance
G4 antimicrobial drug resistanceG4 antimicrobial drug resistance
G4 antimicrobial drug resistance
 
Monoclonal antibodies
Monoclonal antibodiesMonoclonal antibodies
Monoclonal antibodies
 
Seminario Biología Molecular
Seminario Biología MolecularSeminario Biología Molecular
Seminario Biología Molecular
 
Monoclonal antibody and its delivery
Monoclonal antibody and its deliveryMonoclonal antibody and its delivery
Monoclonal antibody and its delivery
 
Physical method of transformation
Physical method of transformation Physical method of transformation
Physical method of transformation
 
viral nanoparticles
viral nanoparticlesviral nanoparticles
viral nanoparticles
 
Pathogenesis of Mycoplasmosis
Pathogenesis of MycoplasmosisPathogenesis of Mycoplasmosis
Pathogenesis of Mycoplasmosis
 
Monoclonal antibodies in cancer therapy
Monoclonal antibodies in cancer therapy Monoclonal antibodies in cancer therapy
Monoclonal antibodies in cancer therapy
 

En vedette (9)

1ormoni
1ormoni1ormoni
1ormoni
 
1a characterization
1a characterization1a characterization
1a characterization
 
4colesterolo tg
4colesterolo tg4colesterolo tg
4colesterolo tg
 
2 diabete
2 diabete2 diabete
2 diabete
 
9bmuscolo
9bmuscolo9bmuscolo
9bmuscolo
 
2 glicemia bt
2 glicemia bt2 glicemia bt
2 glicemia bt
 
FEGATO + ETANOLO
FEGATO + ETANOLOFEGATO + ETANOLO
FEGATO + ETANOLO
 
11membranes4
11membranes411membranes4
11membranes4
 
5cancer
5cancer5cancer
5cancer
 

Similaire à Surface Modification of Nanoparticles for Biomedical Applications

Engineered scaffold protein
Engineered scaffold proteinEngineered scaffold protein
Engineered scaffold proteinDRMOHITKHER
 
Aptamer and its applications
Aptamer and its applicationsAptamer and its applications
Aptamer and its applicationsAchyut Bora
 
Principles of immunodetection
Principles of immunodetectionPrinciples of immunodetection
Principles of immunodetectiondream10f
 
A panel of recombinant monoclonal antibodies against zebrafish
A panel of recombinant monoclonal antibodies against zebrafishA panel of recombinant monoclonal antibodies against zebrafish
A panel of recombinant monoclonal antibodies against zebrafishShahnaz Yusaf
 
APTAMERS
APTAMERS APTAMERS
APTAMERS ROHIT
 
Aptamers and antisense oligonucleotides
Aptamers and antisense oligonucleotidesAptamers and antisense oligonucleotides
Aptamers and antisense oligonucleotidesSagugowda
 
GENE Expression TARGETED THERAPY.pdf
GENE Expression  TARGETED THERAPY.pdfGENE Expression  TARGETED THERAPY.pdf
GENE Expression TARGETED THERAPY.pdfmohieeldien elsayed
 
Aptamer :A Novel Therapeutic Oligonucleotide
Aptamer :A Novel Therapeutic OligonucleotideAptamer :A Novel Therapeutic Oligonucleotide
Aptamer :A Novel Therapeutic OligonucleotideMahesh Shinde
 
BIOPHARMACEUTICS OF ANTISENSE MOLECULE AND APTAMERS
BIOPHARMACEUTICS  OF  ANTISENSE MOLECULE AND  APTAMERSBIOPHARMACEUTICS  OF  ANTISENSE MOLECULE AND  APTAMERS
BIOPHARMACEUTICS OF ANTISENSE MOLECULE AND APTAMERSMUSTAFIZUR RAHMAN
 
ANTIBODY ENGINEEERING ITS APPLICATIONS
ANTIBODY ENGINEEERING  ITS APPLICATIONS ANTIBODY ENGINEEERING  ITS APPLICATIONS
ANTIBODY ENGINEEERING ITS APPLICATIONS sana sana
 
Biopharmaceutics of antisense molecule and aptamers
Biopharmaceutics of antisense molecule and aptamersBiopharmaceutics of antisense molecule and aptamers
Biopharmaceutics of antisense molecule and aptamersSUJITHA MARY
 
monoclonal antibodies and engineered antibodies
monoclonal antibodies and engineered antibodiesmonoclonal antibodies and engineered antibodies
monoclonal antibodies and engineered antibodiesMunawar Ali
 
Cell-based Assays for Immunotherapy Drug Development
Cell-based Assays for Immunotherapy Drug DevelopmentCell-based Assays for Immunotherapy Drug Development
Cell-based Assays for Immunotherapy Drug DevelopmentDiscoverX Corporation
 
Inhibition of the mtorc pathway in the antiphospholipid
Inhibition of the mtorc pathway in the antiphospholipidInhibition of the mtorc pathway in the antiphospholipid
Inhibition of the mtorc pathway in the antiphospholipidSaris Arango
 
Directed Evolution
Directed EvolutionDirected Evolution
Directed EvolutionIfrah Ishaq
 

Similaire à Surface Modification of Nanoparticles for Biomedical Applications (20)

targeting
targetingtargeting
targeting
 
3targeting
3targeting3targeting
3targeting
 
Engineered scaffold protein
Engineered scaffold proteinEngineered scaffold protein
Engineered scaffold protein
 
Aptamer and its applications
Aptamer and its applicationsAptamer and its applications
Aptamer and its applications
 
IMMUNOPRECIPITATION
IMMUNOPRECIPITATIONIMMUNOPRECIPITATION
IMMUNOPRECIPITATION
 
Principles of immunodetection
Principles of immunodetectionPrinciples of immunodetection
Principles of immunodetection
 
A panel of recombinant monoclonal antibodies against zebrafish
A panel of recombinant monoclonal antibodies against zebrafishA panel of recombinant monoclonal antibodies against zebrafish
A panel of recombinant monoclonal antibodies against zebrafish
 
APTAMERS
APTAMERS APTAMERS
APTAMERS
 
Aptamers and antisense oligonucleotides
Aptamers and antisense oligonucleotidesAptamers and antisense oligonucleotides
Aptamers and antisense oligonucleotides
 
Recombinant protein
Recombinant proteinRecombinant protein
Recombinant protein
 
GENE Expression TARGETED THERAPY.pdf
GENE Expression  TARGETED THERAPY.pdfGENE Expression  TARGETED THERAPY.pdf
GENE Expression TARGETED THERAPY.pdf
 
Aptamer :A Novel Therapeutic Oligonucleotide
Aptamer :A Novel Therapeutic OligonucleotideAptamer :A Novel Therapeutic Oligonucleotide
Aptamer :A Novel Therapeutic Oligonucleotide
 
BIOPHARMACEUTICS OF ANTISENSE MOLECULE AND APTAMERS
BIOPHARMACEUTICS  OF  ANTISENSE MOLECULE AND  APTAMERSBIOPHARMACEUTICS  OF  ANTISENSE MOLECULE AND  APTAMERS
BIOPHARMACEUTICS OF ANTISENSE MOLECULE AND APTAMERS
 
Recombinant protein
Recombinant proteinRecombinant protein
Recombinant protein
 
ANTIBODY ENGINEEERING ITS APPLICATIONS
ANTIBODY ENGINEEERING  ITS APPLICATIONS ANTIBODY ENGINEEERING  ITS APPLICATIONS
ANTIBODY ENGINEEERING ITS APPLICATIONS
 
Biopharmaceutics of antisense molecule and aptamers
Biopharmaceutics of antisense molecule and aptamersBiopharmaceutics of antisense molecule and aptamers
Biopharmaceutics of antisense molecule and aptamers
 
monoclonal antibodies and engineered antibodies
monoclonal antibodies and engineered antibodiesmonoclonal antibodies and engineered antibodies
monoclonal antibodies and engineered antibodies
 
Cell-based Assays for Immunotherapy Drug Development
Cell-based Assays for Immunotherapy Drug DevelopmentCell-based Assays for Immunotherapy Drug Development
Cell-based Assays for Immunotherapy Drug Development
 
Inhibition of the mtorc pathway in the antiphospholipid
Inhibition of the mtorc pathway in the antiphospholipidInhibition of the mtorc pathway in the antiphospholipid
Inhibition of the mtorc pathway in the antiphospholipid
 
Directed Evolution
Directed EvolutionDirected Evolution
Directed Evolution
 

Plus de Fisiopatologia Bicocca (20)

Esiti bt3 23.01.2017
Esiti bt3 23.01.2017Esiti bt3 23.01.2017
Esiti bt3 23.01.2017
 
Esiti esame masserini 13 12_16
Esiti esame masserini 13 12_16Esiti esame masserini 13 12_16
Esiti esame masserini 13 12_16
 
10 rene
10 rene10 rene
10 rene
 
Esercitazione b
Esercitazione bEsercitazione b
Esercitazione b
 
Esercitazione a
Esercitazione aEsercitazione a
Esercitazione a
 
9 fegato
9 fegato9 fegato
9 fegato
 
8 colesterolo
8 colesterolo8 colesterolo
8 colesterolo
 
7 ros-rl
7 ros-rl7 ros-rl
7 ros-rl
 
6 snc
6 snc6 snc
6 snc
 
5 collagene 2016
5 collagene 20165 collagene 2016
5 collagene 2016
 
Stage BT3 2016 2017
Stage BT3 2016 2017Stage BT3 2016 2017
Stage BT3 2016 2017
 
4 calcio
4 calcio4 calcio
4 calcio
 
Esercitazione del 26.10.2016
Esercitazione del 26.10.2016Esercitazione del 26.10.2016
Esercitazione del 26.10.2016
 
3 sangue
3 sangue3 sangue
3 sangue
 
2 lipoproteine
2 lipoproteine2 lipoproteine
2 lipoproteine
 
1 glicemia
1 glicemia1 glicemia
1 glicemia
 
Esiti bt3 04.10.2016
Esiti bt3 04.10.2016Esiti bt3 04.10.2016
Esiti bt3 04.10.2016
 
Esame del 06.09.2016
Esame del 06.09.2016Esame del 06.09.2016
Esame del 06.09.2016
 
Esame del 19.07.2016
Esame del 19.07.2016Esame del 19.07.2016
Esame del 19.07.2016
 
esito Esame Bioch SiSt Umana del 21.06.2016
esito Esame Bioch SiSt Umana del 21.06.2016esito Esame Bioch SiSt Umana del 21.06.2016
esito Esame Bioch SiSt Umana del 21.06.2016
 

Surface Modification of Nanoparticles for Biomedical Applications

  • 1. Surface Modification of Nanoparticles for Biomedical Applications 1 1
  • 2.
  • 3.
  • 4. • Consequently a multi-component nanomedical system can be constructed in reverse order of controlling events, namely from the inside out. The outer components are the first to be used. The inner components are the last.
  • 5.
  • 7. The drug can be inserted into the core
  • 9.
  • 10.
  • 11.
  • 12.
  • 13. Cell Targeting A. antibodies B. Peptides C. Aptamers D. Other ligands
  • 14. Antibodies • Antibodies directed against tissue-specific antigens.
  • 15. Examples Receptors: Vascular endothelial growth factor (VEGF); folate (highly expressed in tumours); Transferrin, opiod peptides (Brain), Apolipoproteins (ApoE, Brain) , Human epidermal growth factor (EGF) αvβ3 Integrin Matrix metalloproteinases
  • 16.
  • 17.
  • 19. Aptamers are oligonucleic acid molecules that bind a specific target molecule. Aptamers are usually created by selecting them from a large random sequence pool, but natural aptamers also exist in riboswitches. Aptamers can be used for both basic research and clinical purposes as macromolecular drugs.
  • 20. • aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications.
  • 21.
  • 22.
  • 23. Aptamer target protein or molecule Application PSMA Prostate cancer diagnosis and therapy WT1 Understanding Wilm's tumor pathogenesis 4,4′-methylenedianiline Detecting DNA-damaging compounds VEGF Inhibiting angiogenesis RET Inhibition of pro-growth signaling HER-3 Reducing drug resistance in HER-2+ cancers TCF-1 Colon cancer growth inhibition Tenascin-C Glioblastoma (brain cancer) detection MUC1 Breast, pancreatic, ovarian cancers; targeting demonstrated PDGF/PDGFR Improving transport to tumors and targeting brain cancers NF-κB Targeting a transcription factor implicated in many diseases Phosphatidylcholine:cholesterol liposomes Triggering liposome degradation Raf-1 Inhibiting pro-growth signaling αvβ3 integrin Targeting tumor-associated vasculature Human keratinocyte growth factor Inhibiting pro-growth signali
  • 24. Properties of aptamers versus antibodies Aptamers Antibodies Binding affinity nanomolar to picomolar Binding affinity nanomolar to picomolar Selection is a chemical process carried out Selection requires a biological system, in vitro and can therefore target any thus it is difficult to raise antibodies protein to toxins (not tolerated by animal) or non- Can select for ligands under a variety of immunogenic targets. conditions for in vitro diagnostics Limited to physiologic conditions for diagnostics Uniform activity regardless of batch Screening monoclonal antibodies time synthesis consuming and expensive PK parameters can be changed on demand Activity of antibodies vary from batch to Investigator determines target site of batch protein Difficult to modify PK parameters Wide variety of chemical modifications to Immune system determines target site of molecule for diverse functions of molecule protein Return to original conformation after Temperature sensitive and undergo temperature insult irreversible denaturation Limited shelf-life Unlimited shelf-life Significant immunogenicity No evidence of immunogenicity
  • 25. PEPTIDES • Peptide sequences recognized by receptors responsible of binding can be identified and synthesized. • Examples are peptide sequences derived from ApoE apolipoprotein that are recognized by LDL receptor on cell membranes
  • 26. Peptides aptamers • Peptide aptamers consist of a variable peptide loop attached at both ends to a protein scaffold. This double structural constraint greatly increases the binding affinity of the peptide aptamer to levels comparable to an antibody's (nanomolar range).The variable loop length is typically comprised of 10 to 20 amino acids, and the scaffold may be any protein which has good solubility and compacity properties. Currently, the bacterial protein Thioredoxin-A is the most used scaffold protein, the variable loop being inserted within the reducing active site, which is a -Cys-Gly-Pro-Cys- loop in the wild protein, the two Cysteines lateral chains being able to form a disulfide bridge.Peptide aptamer selection can be made using different systems, but the most used is currently the yeast two- hybrid system.
  • 27. OTHER LIGANDS • Natural ligands for receptors can be employed. Examples: Folate ApoE Trasferrin
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 36.
  • 37. nanoparticle nanoparticle biotin streptavidin biotin
  • 38. antibody nanoparticle antibody streptavidin biotin
  • 39.
  • 40.
  • 41. LNA • A locked nucleic acid (LNA), often referred to as inaccessible RNA, is a modified RNA nucleotide. The ribose moiety is modified with an extra bridge connecting the 2' oxygen and 4' carbon. LNA nucleotides can be mixed with DNA or RNA residues in the oligonucleotide whenever desired. Such oligomers are commercially available. The locked ribose conformation enhances base stacking and backbone pre- organization. This significantly increases the hybridization properties (melting temperature) of oligonucleotides.[1]
  • 42.
  • 43.
  • 44.
  • 45.